Vladivostok, Russia’s Federal Medical and Biological Agency (FMBA) has unveiled a groundbreaking cancer vaccine named Enteromix, which has shown remarkable results in early-stage trials. The announcement was made during the Eastern Economic Forum by FMBA head Veronika Skvortsova.
The vaccine, based on mRNA technology similar to that used in COVID-19 vaccines, is designed to treat cancer after diagnosis by training the immune system to target and destroy tumor cells. Unlike traditional treatments Enteromix is fully personalized tailored to each patient’s unique tumor RNA profile.
🔬 Key Trial Highlights:
- Tested on 48 patients with colorectal cancer
- Achieved 60–80% tumor reduction
- No serious side effects reported
- Improved survival rates observed
- Future applications may include glioblastoma and ocular melanoma
Skvortsova stated that the vaccine is “ready for clinical use,” pending approval from Russia’s Ministry of Health. However, international experts urge caution, noting the need for peer-reviewed data and broader clinical trials before global rollout.
If successful, Enteromix could mark a major shift in cancer treatment, offering a safer and more targeted alternative to chemotherapy and radiation.